PI3K/p110β-specific inhibitors in castration-resistant prostate cancer
LI Ben-yi
WU Jian-hong
Abstract：Advanced prostate cancer,especially at the castration-resistant stage,remains incurable clinically and,therefore,urgently requires new therapeutics for the patients.PI3K is a family of critical cell signal transduction molecules and their over-activation is an important factor in cancer development and progression.It has been demonstrated that class IA PI3K p110 is drastically overexpressed in prostate cancer and involved in androgen receptor-mediated gene expression and castration-resistant progression and regarded as a potential therapeutic target for prostate cancer.Several p110-specific inhibitors have been reported recently and two of them,GSK2636771 and AZD8186,are being tested in clinical trials.
Keywords：p110-specific inhibitorstargeted therapyadvanced prostate cancercastration-resistance
Publication Date：2017-03-02
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 195-199 )